Prakiraan wutah bathi resik saben saham kanggo taun ngarep Nuvectis (NVCT)

Logo korporat perusahaan Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma, Inc. (NVCT) operates in a high-risk zone where the competition with global behemoths over clinical trial timelines determines success. Patents for kinase inhibitors and strict FDA oversight serve as defensive assets. The implementation of laboratory robotics accelerates molecule discovery. This chart of EPS growth prospects for the next fiscal year shows that the figure is 16.60.

Nuvectis (NVCT): Prakiraan wutah bathi resik saben saham kanggo taun ngarep saka 04.07.2022 nganti 16.11.2026

Ringkesan rincian data analitis Nuvectis (NVCT)

- rega saham lan konsensus proyeksi valuasi:
Analisis fundamental perusahaan:Nuvectis Pharma, Inc.
Produk dadi Nuvectis Pharma Inc.

Analyzing the projected EPS growth for the next fiscal year, we assess the status of Nuvectis Pharma, Inc. (NVCT) as a virtual biopharmaceutical player. This indicator reflects the consensus forecast for earnings per share changes, signaling an upcoming revaluation of the business value. The metric's trend is sensitive to costs associated with third-party contractors (CRO/CMO), which are critical for conducting trials. The stability of the curve confirms the resilience of patents against operational outsourcing risks.

Analisis pesaing Nuvectis Pharma, Inc.

INCY (incyte.com) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep hutch-med.com HCM|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Nuvation Corp (NUVB)|DAWN - Prakiraan wutah bathi resik saben saham ing taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Monopar Pharma MNPR|Inhibrx Corp - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|IMAB - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep Fennec Pharmaceuticals|HRTX: Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben siji saham kanggo taun ngarep Coherus CHRS|Prakiraan wutah bathi saben saham kanggo taun ngarep CRBP|Prakiraan wutah bathi resik saben saham ing taun ngarep Cardiff Oncology CRDF|Prakiraan wutah bathi saben saham kanggo taun ngarep BYSI (BeyondSpring Inc.)|BCAB (BioAtla Corp) - Dinamika bathi saben saham sing diarepake ing taun ngarep|Lixte Biotechnology - Prakiraan wutah bathi saben saham kanggo taun ngarep|Proyeksi tambahing bathi saben saham ing taun ngarep CTXR (Citius Pharma)|Cellectar - Prakiraan wutah bathi kanggo taun ngarep|Dinamika bathi saben saham sing diarepake ing taun ngarep BLRX (BioLineRx Corp)|CANF: Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep Aprea (APRE)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep kaziatherapeutics.com|SLXN: Dinamika bathi saben saham sing diarepake ing taun ngarep|Prakiraan wutah bathi kanggo taun ngarep NCNA|Prakiraan wutah bathi kanggo taun ngarep Chimerix Inc (CMRX)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Cyclacel Pharmaceuticals Inc. CYCC|GTHX (g1therapeutics.com) - Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep|KRON: Prakiraan wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep Kintara Therapeutics Inc|oncternal.com (ONCT) - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep PRTG (Portage Biotech Corp)